We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+30.6%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$450M
AUM Growth
+$163M
Cap. Flow
+$151M
Cap. Flow %
33.61%
Top 10 Hldgs %
64.43%
Holding
49
New
11
Increased
19
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$25.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$19.1M
3
TSRO
TESARO, Inc.
TSRO
+$16.2M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$15.2M
5
DERM
Dermira, Inc.
DERM
+$15.1M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$8.91M
2
GILD icon
Gilead Sciences
GILD
+$5.94M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$5.92M
4
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$4.08M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.02M

Sector Composition

Rank Sector Weight
1 Healthcare 73.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$43.2M 9.6%
514,000
+364,000
+243% +$16.2M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$2.04B
$35.1M 7.81%
4,338,557
+1,213,359
+39% +$7.62M
CPXX
3
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$33.9M 7.54%
1,124,666
-291,591
-21% -$5.92M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.9B
$33.7M 7.49%
432,972
+155,700
+56% +$13.2M
BMY icon
5
Bristol-Myers Squibb
BMY
$129B
$32.8M 7.28%
445,339
+270,339
+154% +$19.1M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.64B
$26.9M 5.98%
1,412,190
+257,190
+22% +$4.76M
NBIX icon
7
Neurocrine Biosciences
NBIX
$18.2B
$23.1M 5.14%
509,330
+104,010
+26% +$4.79M
DERM
8
DELISTED
Dermira, Inc.
DERM
$21.1M 4.69%
721,663
+546,663
+312% +$15.1M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$20.2M 4.49%
3,698,665
+274,561
+8% +$1.92M
IMMU
10
DELISTED
Immunomedics Inc
IMMU
$19.9M 4.41%
8,556,957
+7,506,500
+715% +$25.1M
MDVN
11
DELISTED
MEDIVATION, INC.
MDVN
$16.9M 3.75%
279,700
+9,035
+3% +$512K
GBT
12
DELISTED
Global Blood Therapeutics, Inc.
GBT
$16M 3.55%
963,646
+755,560
+363% +$15.2M
AGEN
13
Agenus
AGEN
$276M
$12.6M 2.79%
157,937
+35,613
+29% +$2.78M
RLYP
14
DELISTED
RELYPSA INC COM
RLYP
$11.3M 2.52%
+613,300
New +$10.8M
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$4.51B
$10.7M 2.38%
+329,500
New +$11M
SRNE
16
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$9.27M 2.06%
1,655,274
+509,495
+44% +$3.26M
TLGT
17
DELISTED
Teligent, Inc
TLGT
$9.21M 2.05%
129,000
+36,500
+39% +$2.12M
GILD icon
18
Gilead Sciences
GILD
$165B
$9.05M 2.01%
108,500
-66,900
-38% -$5.94M
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$9.05M 2.01%
557,003
+19,526
+4% +$329K
VNDA icon
20
Vanda Pharmaceuticals
VNDA
$304M
$7.94M 1.76%
709,579
-145,000
-17% -$1.4M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.63M 1.47%
1,214,833
-189,222
-13% -$3.02M
CASC
22
DELISTED
Cascadian Therapeutics, Inc.
CASC
$5.42M 1.2%
957,454
+279,275
+41% +$1.9M
CYTK icon
23
Cytokinetics
CYTK
$10.6B
$4.78M 1.06%
+503,900
New +$4.13M
AKBA icon
24
Akebia Therapeutics
AKBA
$338M
$4.65M 1.03%
+621,873
New +$5.43M
VCYT icon
25
Veracyte
VCYT
$4.45B
$4.62M 1.03%
918,556
+188,042
+26% +$1.01M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Avoro Capital Advisors held 49 positions worth $450M, up 57% from $287M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Avoro Capital Advisors deployed $151M of net new capital in Q2 2016, opening 11 new positions and adding to 19 existing holdings. Its largest new stake was Acadia Pharmaceuticals: 329,500 shares worth $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 81% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $5.94M trimmed.

  • Avoro Capital Advisors's largest Q2 2016 buy was Acadia Pharmaceuticals: 329,500 shares worth $10.7M.
  • Avoro Capital Advisors added most to Immunomedics Inc in Q2 2016, an estimated $25.1M increase.
  • Avoro Capital Advisors's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $5.94M.
  • Avoro Capital Advisors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $8.91M.
  • Avoro Capital Advisors's ten largest holdings make up 64% of its $450M portfolio in Q2 2016.
  • Avoro Capital Advisors opened 11 new positions and closed 7 in Q2 2016.
  • Avoro Capital Advisors's portfolio value rose 57% quarter-over-quarter to $450M.

Based on Avoro Capital Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.